Orchestra BioMed appoints former Medtronic SVP Chris Cleary to board; Dr. Eric Rose resigns as director

Orchestra BioMed Holdings, Inc.

Chris Cleary appointed as Class II independent director effective Jan 30, 2025; board expanded to nine.
Cleary was Medtronic SVP of Corporate Development, led $50B Covidien acquisition and $6B asset sale to Cardinal Health.
Cleary previously helped shape Orchestra BioMed's AVIM therapy strategic collaboration with Medtronic.
Eric Rose resigned as director Feb 3, 2025; remains as Emeritus Board Member and Strategic Advisor.
Board expected to decrease to eight members following Rose resignation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Chris Cleary

Class II director

OBIO · Orchestra BioMed Holdings, Inc.

Effective: 2025-01-30
Filed: February 5, 2025, 6:59 PM ET

appointed Chris Cleary to serve as a Class II director, effective immediately

Departed

Eric Rose

director

OBIO · Orchestra BioMed Holdings, Inc.

Effective: 2025-02-03
Filed: February 5, 2025, 6:59 PM ET

On February 3, 2025, Eric Rose, M.D., notified the Company of his resignation from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Cleary was appointed as Class II director at Orchestra BioMed Holdings, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

appointed Chris Cleary to serve as a Class II director, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Rose resigned as director at Orchestra BioMed Holdings, Inc..

Action: resigned
Role: director

Exact text from the filing

On February 3, 2025, Eric Rose, M.D., notified the Company of his resignation from the Board, effective immediately.

View on SEC.gov

Orchestra BioMed Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-009393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.